Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05236387
Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection
Overview
The purpose of the present study is to evaluate the ability of 99mTc-TM to identify the clipped node after neoadjuvant chemotherapy (NAC) and to compare this percentage with historical national data. This study will also evaluate pain and discomfort after injection and pathological features of clipped nodes and any additional nodes removed.
Sponsor
Johns Hopkins University
Contacts
Mehran Habibi, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT05236387Eligibility
Inclusion
- The patient has been diagnosed with invasive Stage 2-3 breast cancer (T1-3; N1-2).
- The patient has no history of inflammatory breast cancer.
- The patient has no matted node on examination (N3).
- The patient is a candidate for surgical intervention, with sentinel lymph node assessment being a part of the surgical plan.
- The patient is eligible for neoadjuvant chemotherapy (NAC).
Exclusion
- The patient has clinical and/or radiological evidence of metastatic or systemic disease. Oligo metastatic disease is acceptable (one organ and controlled).
Share your feedback
Help us improve your experience